Novacap completes the acquisition of Rhodia’s analgesic activities
Novacap has completed the carve-out of Rhodia’s salicylic and acetaminophen businesses, with the support of its majority shareholder AXA Private Equity. These activities will become Novacyl, a newly created company within Novacap. Novacyl generates revenues of EUR100 million per year and employs approximately 360 people, with production sites located in

